Morepen Labs posts strong Q4 FY26 net profit
For the full year, standalone gross revenue crossed Rs. 1,700 crore
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Sheshadri brings with him extensive leadership experience spanning healthcare, diagnostics, telecom, and consumer goods industries
The company reported free cash flow of Rs. 2,590 Mn for FY26
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated